Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05032820 · ClinicalTrials.gov registry record · Phase 2
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT05032820 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 40 participants.
The verdict
NCT05032820, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Lenalidomide
- PROCEDURE leukapheresis
- BIOLOGICAL bb2121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-01-05 |
| Est. Completion | 2025-02-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05032820
The ClinicalTrials.gov registry entry for NCT05032820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05032820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05032820 about?
NCT05032820 is a clinical study titled "Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma". This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).
What is the current status of trial NCT05032820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2022-01-05. Estimated completion is 2025-02-20.
What interventions are being tested in trial NCT05032820?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Lenalidomide (DRUG), leukapheresis (PROCEDURE), bb2121 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05032820?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.